MX2015010347A - Compuestos biciclicos. - Google Patents

Compuestos biciclicos.

Info

Publication number
MX2015010347A
MX2015010347A MX2015010347A MX2015010347A MX2015010347A MX 2015010347 A MX2015010347 A MX 2015010347A MX 2015010347 A MX2015010347 A MX 2015010347A MX 2015010347 A MX2015010347 A MX 2015010347A MX 2015010347 A MX2015010347 A MX 2015010347A
Authority
MX
Mexico
Prior art keywords
compounds
disclosed
bicyclic compounds
diseases
slowing
Prior art date
Application number
MX2015010347A
Other languages
English (en)
Spanish (es)
Inventor
T G Murali Dhar
Alaric J Dyckman
Daniel Richard Roberts
Marta Dabros
Hai-Yun Xiao
Eric J Chan
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2015010347A publication Critical patent/MX2015010347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
MX2015010347A 2013-02-21 2014-02-21 Compuestos biciclicos. MX2015010347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (1)

Publication Number Publication Date
MX2015010347A true MX2015010347A (es) 2015-11-16

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010347A MX2015010347A (es) 2013-02-21 2014-02-21 Compuestos biciclicos.

Country Status (34)

Country Link
US (3) US9115054B2 (enExample)
EP (1) EP2958888B1 (enExample)
JP (1) JP6277210B2 (enExample)
KR (1) KR102242265B1 (enExample)
CN (1) CN105026362B (enExample)
AR (1) AR094851A1 (enExample)
AU (1) AU2014218883B2 (enExample)
BR (1) BR112015019919A2 (enExample)
CA (1) CA2902168C (enExample)
CL (1) CL2015002358A1 (enExample)
CY (1) CY1118641T1 (enExample)
DK (1) DK2958888T3 (enExample)
EA (1) EA025294B1 (enExample)
ES (1) ES2613262T3 (enExample)
HR (1) HRP20170247T1 (enExample)
HU (1) HUE031626T2 (enExample)
IL (1) IL240613B (enExample)
LT (1) LT2958888T (enExample)
MA (1) MA38425B1 (enExample)
MX (1) MX2015010347A (enExample)
MY (1) MY173990A (enExample)
PE (1) PE20151746A1 (enExample)
PH (1) PH12015501793A1 (enExample)
PL (1) PL2958888T3 (enExample)
PT (1) PT2958888T (enExample)
RS (1) RS55703B1 (enExample)
SG (1) SG11201506408TA (enExample)
SI (1) SI2958888T1 (enExample)
SM (2) SMT201700115T1 (enExample)
TN (1) TN2015000356A1 (enExample)
TW (1) TWI613182B (enExample)
UY (1) UY35338A (enExample)
WO (1) WO2014130752A2 (enExample)
ZA (1) ZA201506965B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022176B8 (en) 2013-07-15 2019-12-25 The Regents of the University of California Azacyclic constrained analogs of fty720
UY36274A (es) * 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
WO2017053990A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
US10633354B2 (en) 2016-09-02 2020-04-28 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
US7351725B2 (en) 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
ES2467160T3 (es) 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1863463A1 (en) 2005-02-14 2007-12-12 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups
EP1858840A2 (en) 2005-02-18 2007-11-28 Innodia Inc. Analogs of 4-hydroxyisoleucine and uses thereof
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
PT1863474E (pt) 2005-03-23 2009-01-20 Actelion Pharmaceuticals Ltd Novos derivados de tiofeno como agonistas dos receptores 1 de esfingosina-1-fosfato
DE602006015297D1 (de) 2005-04-22 2010-08-19 Daiichi Sankyo Co Ltd 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
EP1917240A1 (en) 2005-08-23 2008-05-07 Irm Llc Immunosuppressant compounds and compositions
JP5432526B2 (ja) 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
BRPI0707281A2 (pt) 2006-01-27 2011-04-26 Univ Virginia método para prevenção ou tratamento de dor neuropática em um mamìfero
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
CL2007000742A1 (es) 2006-03-21 2008-01-11 Epix Delaware Inc Compuestos derivados de 2-oxoimidazol, moduladores del recptor s1p (esfingosina-1-fosfato); composicion farmceutica que los contiene; y su uso para tratar condiciones tales como rechazo de trasplante, cancer, artritis reumatoide y diabetes.
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
JP2010513532A (ja) * 2006-12-21 2010-04-30 アボット・ラボラトリーズ スフィンゴシン−１−ホスフェート受容体作働薬および拮抗薬化合物
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
WO2008114157A1 (en) 2007-03-16 2008-09-25 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009124022A1 (en) 2008-04-01 2009-10-08 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
AU2009327133B2 (en) 2008-12-18 2016-04-14 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2382211B1 (en) 2009-01-23 2012-12-19 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
CN102361869A (zh) * 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
CN102316862A (zh) 2009-02-10 2012-01-11 雅培制药有限公司 制备s1p受体激动剂或拮抗剂的方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
KR20130036171A (ko) 2009-10-29 2013-04-11 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 헤테로시클릭 화합물
CN103119038B (zh) 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
EP2685971A4 (en) 2011-03-18 2014-01-22 Univ Virginia Patent Found COMPOSITIONS AND METHODS FOR TISSUE PROCESSING AND CELL-BASED THERAPIES
EP2541155B1 (en) 2011-04-26 2016-02-24 Panasonic Intellectual Property Management Co., Ltd. Heating system, and heating system control method
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
KR102127025B1 (ko) 2012-07-27 2020-06-25 비오겐 엠에이 아이엔씨. S1p 조절제 및/또는 atx 조절제인 화합물들

Also Published As

Publication number Publication date
AU2014218883A1 (en) 2015-10-15
LT2958888T (lt) 2017-02-10
HUE031626T2 (en) 2017-07-28
US20160251309A1 (en) 2016-09-01
MY173990A (en) 2020-03-03
IL240613B (en) 2018-06-28
MA38425A1 (fr) 2017-12-29
IL240613A0 (en) 2015-10-29
UY35338A (es) 2014-08-29
US9487481B2 (en) 2016-11-08
HK1218111A1 (en) 2017-02-03
US9359286B2 (en) 2016-06-07
JP6277210B2 (ja) 2018-02-07
SMT201700115B (it) 2017-03-08
KR20150119352A (ko) 2015-10-23
TN2015000356A1 (en) 2017-01-03
ZA201506965B (en) 2017-08-30
SI2958888T1 (sl) 2017-01-31
PE20151746A1 (es) 2015-12-02
TW201444786A (zh) 2014-12-01
PL2958888T3 (pl) 2017-07-31
SG11201506408TA (en) 2015-09-29
AR094851A1 (es) 2015-09-02
TWI613182B (zh) 2018-02-01
US20150315128A1 (en) 2015-11-05
JP2016513124A (ja) 2016-05-12
US20140235591A1 (en) 2014-08-21
PH12015501793B1 (en) 2015-11-09
WO2014130752A3 (en) 2014-10-23
CY1118641T1 (el) 2017-07-12
PH12015501793A1 (en) 2015-11-09
SMT201700115T1 (it) 2017-03-08
CN105026362A (zh) 2015-11-04
CA2902168A1 (en) 2014-08-28
KR102242265B1 (ko) 2021-04-19
US9115054B2 (en) 2015-08-25
RS55703B1 (sr) 2017-07-31
ES2613262T3 (es) 2017-05-23
EA201591409A1 (ru) 2015-12-30
EP2958888A2 (en) 2015-12-30
CN105026362B (zh) 2017-07-14
HRP20170247T1 (hr) 2017-04-07
PT2958888T (pt) 2017-02-03
EP2958888B1 (en) 2016-11-23
DK2958888T3 (en) 2017-03-06
CL2015002358A1 (es) 2016-02-26
AU2014218883B2 (en) 2017-05-11
MA38425B1 (fr) 2019-03-29
CA2902168C (en) 2019-01-08
BR112015019919A2 (pt) 2017-07-18
EA025294B1 (ru) 2016-12-30
WO2014130752A2 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
TN2015000356A1 (en) Bicyclic compounds
WO2017087608A8 (en) Modulators of ror-gamma
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MY179783A (en) Substituted bicyclic compounds
MX2015016416A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
TN2017000158A1 (en) Carbazole derivatives
HK1217092A1 (zh) 治疗性化合物及其用途
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
MY201535A (en) Therapeutic compounds
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12017501736B1 (en) Indole derivatives
HK1245077A1 (en) Compositions and methods of treating a neurodegenerative disease
TH174557A (th) สารประกอบไบไซคลิคซึ่งถูกแทนที่